What are the recommended diagnostic steps and management strategies for bronchiectasis?

Bronchiectasis Diagnosis and Treatment

All patients with suspected bronchiectasis require thin-section CT chest imaging for definitive diagnosis, followed by standardized testing to identify underlying causes including immunoglobulins, ABPA serology, and NTM cultures, with management centered on airway clearance techniques and risk-stratified antibiotic therapy based on exacerbation frequency and pathogen colonization. 1, 2

Diagnostic Approach

When to Suspect Bronchiectasis

Investigate for bronchiectasis in patients presenting with:

• Persistent mucopurulent or purulent sputum production with relevant risk factors 2
• Chronic productive cough lasting >8 weeks 2
• Recurrent chest infections
• Unexplained hemoptysis 3

High-risk populations requiring lower threshold for investigation:

• Rheumatoid arthritis with chronic productive cough or recurrent infections 2
• COPD with ≥2 exacerbations annually AND positive P. aeruginosa culture while stable 2
• Inflammatory bowel disease with chronic productive cough 2
• Severe or poorly-controlled asthma 2
• Immunosuppressed patients (HIV, transplant recipients, lymphoma/vasculitis treatment) 2
• Chronic rhinosinusitis with chronic productive cough 2

Imaging Protocol

Perform baseline chest X-ray initially, but thin-section CT is required to confirm diagnosis 2. CT should be obtained during clinical stability for optimal diagnostic accuracy and serial comparison 2.

CT diagnostic criteria for bronchiectasis:

• Bronchoarterial ratio >1 (internal airway lumen vs adjacent pulmonary artery)
• Lack of bronchial tapering
• Airway visibility within 1 cm of costal pleural surface or touching mediastinal pleura 2

Mandatory Baseline Investigations

All newly diagnosed patients require standardized testing 1:

Immunologic screening:

• Serum immunoglobulins (IgG, IgM, IgA) to detect immunodeficiency 1
• Serum protein electrophoresis if immunoglobulins are elevated 2

ABPA screening:

• Total IgE
• Aspergillus-specific IgG and IgE
• Blood eosinophil count 1

Microbiologic evaluation:

• Sputum for mycobacterial microscopy and culture (NTM screening) 1
• For high-risk NTM patients (based on clinical/radiological features): minimum three sputum samples or bronchoalveolar lavage 1
• Routine bacterial culture 1

Additional testing based on clinical features:

• Alpha-1 antitrypsin: NOT routine; only if basal emphysema or severe airflow obstruction present 1
• CF and PCD screening: if symptom onset in childhood OR specific clinical/radiological features at any age 1
• Bronchoscopy: for localized disease to exclude endobronchial lesion or foreign body 2
• Bronchial aspiration/wash: in non-expectorating patients, particularly helpful for NTM diagnosis 2

Severity Assessment and Risk Stratification

Calculate Bronchiectasis Severity Index (BSI) at diagnosis to assess risk of future complications 1. This guides follow-up frequency and treatment thresholds.

Identify high-risk patients requiring intensive management 1:

• COPD, PCD, or rheumatoid arthritis-associated bronchiectasis
• Pseudomonas aeruginosa or other enteric Gram-negative infections
• ≥2 exacerbations per year OR ≥1 severe exacerbation (hospitalization/IV antibiotics) in previous year
• Severe symptoms: high daily sputum volume and purulence
• NTM infection
• ABPA

Comorbidity Assessment

Screen all patients for 1:

• Cardiovascular disease (in at-risk patients)
• Osteoporosis (in at-risk patients)
• Anxiety and depression symptoms
• Rhinosinusitis
• Gastroesophageal reflux disease

Management Strategies

Non-Pharmacological Interventions

Airway clearance techniques are foundational 2:

• Offer active cycle of breathing techniques OR oscillating positive expiratory pressure 2
• Consider gravity-assisted positioning (where not contraindicated) to enhance effectiveness 2
• Must be taught by respiratory physiotherapist 2
• Review CT imaging to guide appropriate postural drainage positions 2
• Patients admitted with exacerbations require daily physiotherapy until airway clearance optimized 2

Pulmonary rehabilitation should be considered as part of comprehensive management 4, 5.

Acute Exacerbation Management

Key principles for exacerbations 2:

• Obtain sputum for culture BEFORE starting antibiotics 2, 3
• Start empirical antibiotics immediately while awaiting culture results 2
• Treatment duration: 14 days 2, 3
• Modify antibiotics based on sensitivity results if no clinical improvement 2

First-line antibiotic choices by pathogen 2:

• Streptococcus pneumoniae: Amoxicillin 500 mg TID
• Haemophilus influenzae (beta-lactamase negative): Amoxicillin 500 mg TID
• Haemophilus influenzae (beta-lactamase positive): Amoxicillin-clavulanate 625 mg TID
• Moraxella catarrhalis: Amoxicillin-clavulanate 625 mg TID

Alternative options include:

• Doxycycline 100 mg BID
• Ciprofloxacin 500-750 mg BID
• Ceftriaxone 2g IV daily

Patients should have antibiotics at home for prompt self-treatment 2. Consider patient self-management plans 2.

Pseudomonas aeruginosa Eradication

For new growth of P. aeruginosa with clinical deterioration 2:

First-line eradication:

• Ciprofloxacin 500-750 mg BID for 2 weeks 2

Second-line eradication:

• IV anti-pseudomonal beta-lactam ± IV aminoglycoside for 2 weeks
• Followed by 3-month course of nebulized colistin, gentamicin, or tobramycin 2

For new P. aeruginosa growth in stable disease: Discuss risks/benefits of eradication treatment versus clinical observation, considering likelihood of sustained eradication, risk of chronic infection, and adverse event risk 2.

MRSA Management

Offer eradication antibiotic treatment for new MRSA growth with clinical deterioration (first isolation or regrowth with intermittently positive cultures) 2.

Long-Term Antibiotic Therapy

Consider for high-risk patients 1, 4:

• Those with ≥2 exacerbations per year
• Chronic P. aeruginosa colonization
• Severe disease with frequent hospitalizations

Options include inhaled antibiotics (colistin, gentamicin, tobramycin) or long-term macrolides, though specific recommendations require specialist guidance 4, 6.

Inhaled Corticosteroids

Limited role in bronchiectasis 4. Unlike asthma and COPD, inhaled corticosteroids are not routinely recommended unless there is coexistent asthma or COPD 4.

Critical Pitfalls to Avoid

1. Do not rely on chest X-ray alone - CT is mandatory for diagnosis 2
2. Do not skip NTM screening - all patients need mycobacterial cultures at baseline 1
3. Do not use short antibiotic courses - 14 days is standard for exacerbations 2, 3
4. Do not forget immunoglobulin testing - treatable immunodeficiency must be identified 1
5. Do not treat bronchiectasis like asthma - inhaled corticosteroids have limited role 4
6. Do not delay sputum culture - obtain before starting antibiotics 2

Ongoing Management

Reassess at all patient visits, not just at diagnosis 1:

• Underlying cause
• Disease activity and severity
• Comorbidities
• Treatable traits
• Treatment burden and quality of life impact

Specialist referral indicated for:

• High BSI scores
• Frequent exacerbations despite optimal management
• P. aeruginosa or NTM infection
• Consideration for long-term antibiotics
• Localized disease potentially amenable to surgery 7